Discovery of tumor markers through platelet proteomics

Completed

• Conditions: Cancer; malignancy; 10027656

• Registration Number: NL-OMON40446
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 44

Inclusion Criteria

-Patients with stage I&II lung and pancreatic malignancies who are eligible for surgical resection.
-Age >18 years
-Histologically confirmed adenocarcinoma
-Hb >5.6 mmol/L

Exclusion Criteria

-Use of any platelet-influencing drug during two weeks prior to blood collection
-Patients with congenital platelet disorder
-Blood or platelet transfusion during two weeks prior to blood collection
-Inflammatory diseases or diabetes
-Serious non-healing wound, ulcer, or bone fracture
-Pregnancy or breast-feeding
-Interference with other research projects

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Net change in platelet angiogenic proteome after surgery.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None</p><br>